PFE
NYSE · Pharmaceuticals
Pfizer Inc.
$27.06
+0.41 (+1.54%)
PFE News10 articles
GSK Stock Dips on Ex-Dividend Date and Arexvy Vaccine Data Release
GSK shares declined 0.4% in early London trading, influenced by the stock going ex-dividend and the release of new real-world effectiveness data for its respiratory syncytial virus vaccine Arexvy.
AbbVie Gains Ahead of Holiday; Investors Eye Pipeline and Pricing
AbbVie shares advanced 1.8% to $231.50 in Friday's session, outpacing peers. Trading volume was elevated as investors assess the company's strategic pivot and regulatory challenges.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
GSK's RSV Vaccine Advances in Chinese Regulatory Review, Eyes 2027 Decision
GSK's Arexvy RSV vaccine application has been accepted for review by China's drug regulator, with a potential approval decision expected in 2027. The stock edged higher as JPMorgan raised its price target and the company's dividend ex-date approaches.
Merck Shares Dip Following Insider Transactions Amid Revenue Forecast Concerns
Merck shares declined 0.5% after SEC filings revealed stock sales by two executives, adding pressure following a revenue outlook that fell short of analyst expectations.
Merck Shares Slide 4% on Patent Concerns and 2026 Outlook
Merck & Co. stock fell nearly 4% Monday, underperforming the broader market as investors reacted to projected patent losses and a cautious 2026 sales forecast.
GSK Nears 52-Week Peak on COPD Drug Approval and U.S. Pricing Developments
GSK shares advanced 0.6% in London trading, approaching a 52-week high following EU approval for Nucala in COPD and amid U.S. drug discount initiatives. Insider trading activity and the upcoming ex-dividend date remain in focus.
Merck Nears 52-Week Peak Amid Insider Sale, Investors Eye Pipeline Updates
Merck shares climbed 1.8% to $121.93, extending gains for a seventh session and approaching a 52-week high. An executive sold 37,685 shares as investors await the impact of 2026 guidance and pipeline developments.
Healthcare Sector Sees Divergence: Molina Plunges on Outlook, XLV Gains Amid Regulatory Warnings
Molina Healthcare plummeted 25.5% after slashing its 2026 profit forecast and announcing a Medicare Part D exit, while the Health Care Select Sector SPDR Fund (XLV) rose 1.8%. Regulatory warnings on compounded obesity drugs added pressure to the sector.
J&J Stock Rises as Court Disqualifies Talc Litigation Firm, AFib Device Data Released
Johnson & Johnson shares gained 0.9% following a New Jersey appeals court decision to remove Beasley Allen from state talc cases and the release of early 12-month data for its investigational AFib device.